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ABSTRACT
Friedreich ataxia (FRDA), the most common heredi-
tary ataxia, is caused by mutations in the frataxin
(FXN) gene. The vast majority of FRDA mutations
involve expansion of a GAA TTC-repeat tract in
intron 1, which leads to an FXN mRNA deficit.
Bisulfite mapping demonstrates that the region
adjacent to the repeat was methylated in both
unaffected and affected individuals. However,
methylation was more extensive in patients.
Additionally, three residues were almost completely
methylation-free in unaffected individuals but
almost always methylated in those with FRDA.
One of these residues is located within an E-box
whose deletion caused a significant drop in pro-
moter activity in reporter assays. Elevated levels of
histone H3 dimethylated on lysine 9 were seen in
FRDA cells consistent with a more repressive
chromatin organization. Such chromatin is known
to reduce transcription elongation. This may be one
way in which the expanded repeats contribute to
the frataxin deficit in FRDA. Our data also suggest
that repeat-mediated chromatin changes may also
affect transcription initiation by blocking binding of
factors that increase frataxin promoter activity. Our
results also raise the possibility that the repeat-
mediated increases in DNA methylation in the FXN
gene in FRDA patients are secondary to the
chromatin changes.
INTRODUCTION
Friedreich ataxia (FRDA) is the most common inherited
ataxia (1). The ataxia, which is recessively inherited, is
relentlessly progressive with patients frequently becoming
wheelchair-bound in their early teens. Hypertrophic
cardiomyopathy is a common co-morbid feature of
FRDA, with congestive heart failure being a frequent
cause of death. The most common cause of FRDA is
the expansion of a GAA TTC-repeat (henceforth referred
to as the FXN repeats) in intron 1 of the frataxin gene
(FXN). Unaﬀected individuals have at least one allele
with 8–33 repeats, while most individuals with FRDA
have 90 or more repeats in both alleles (1). These
expanded alleles produce less mature FXN mRNA than
alleles in the normal range (2,3). This results in a
deﬁciency of frataxin, an essential protein thought to be
involved in mitochondrial iron metabolism (1).
The FXN repeats form an intrinsic block to RNA
polymerase in vitro (4,5), suggesting one potential
mechanism for the FXN mRNA deﬁcit. However, the
FXN repeats may aﬀect transcription in other ways.
For example, the long stretches of tandem repeats present
in normal human centromeres are associated with
transcriptionally silent chromatin (6) as are the genes
containing the expanded triplet repeat tracts responsible
for Fragile X syndrome and congenital myotonic dystro-
phy (7). In addition, transgenes containing long
GAA TTC-tracts become associated with heterochroma-
tin when inserted into arbitrary locations in the mouse
genome (8). It is thus possible that repeat-mediated
chromatin changes also contribute to the reduction in
FXN transcript in FRDA. In principle, changes in
chromatin modiﬁcations in non-coding sequence could
aﬀect transcription by aﬀecting RNA polymerase II
elongation or by changing the accessibility of this region
to regulatory factors important for transcription initiation
(9). Since the ﬁrst intron of many genes contains
regulatory sequences important for gene expression
(10–13) and the sequence adjacent to the FXN repeat is
the region of intron 1 most likely to be aﬀected by repeat
expansion, we examined the contributions of this region
to FXN promoter activity. We also examined the
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this region in cells from unaﬀected individuals and
individuals with FRDA. We have identiﬁed a region
that is important for maximal FXN gene expression and
shown that repeat expansion leads to changes in DNA
methylation and chromatin organization in this region.
Our data also suggests how these changes may lead to the
frataxin deﬁcit responsible for FRDA.
MATERIALS AND METHODS
Insilico analysis of intron1
Primate sequences in the region of intron 1 immediately
50 of the FXN repeat were aligned using the online version
of the Multalin algorithm [(14); http://prodes.toulouse.
inra.fr/multalin/multalin.html]. The repeated DNA
elements in this region were identiﬁed using the Repeat
Masker track generated using the RepBase database (15).
This region was also analyzed for potential transcription
factor binding sites using MatInspector and Matrix
Family Library Version 4.1 (https://www.genomatix.de).
Celllines and DNA
Lymphoblasts from individuals without FRDA
(GM06895, GM06865, GM06891 and GM09145), and
those with FRDA (GM04079, GM15850, GM16207,
GM16209 and GM16243) were obtained from the
Coriell Cell Repository (Camden, NJ). Lymphoblasts
were grown in RPMI 1640 medium supplemented with
10% fetal calf serum under standard conditions
(Invitrogen Life Technologies Inc., Carlsbad, CA).
Genomic DNA was prepared from these cell lines using
standard procedures. The FXN repeat numbers in normal
individuals were determined as described earlier (3,16).
DNA obtained from fresh blood of aﬀected and unaf-
fected individuals was a kind gift of Dr Ed Grabczyk,
Louisiana State University. The plasmid construct
expressing the M.eco72I methylase was a kind gift of
Fermentas AB (Vilnius, Lithuania). The primers and
double-stranded oligonucleotides used were synthesized
by Integrated DNA Technologies (Coralville, IA) and
are listed in Table 1.
DNA methylation analysis
Genomic DNA from cell lines of four unaﬀected and
four aﬀected individuals was bisulphite modiﬁed accord-
ing to standard procedures except that the bisulphite
treatment was carried out overnight at 558C.
The methylation status of the promoter and intron 1
were examined. The promoter was analyzed using the
primers FXNMe74-F and FXNMe956-R. The region 50 of
the GAA repeat in the FXN gene was ampliﬁed by PCR
using the primers FXNMe1212-F and FXNMe1930-R.
The PCR fragments were gel puriﬁed, digested with XhoI
and EcoRI, cloned into pBS SKþ (Stratagene, La Jolla,
CA, USA) and sequenced. Five clones from each
individual were sequenced. The data for each population
was pooled and the frequency with which each residue was
methylated was then plotted along with the standard
deviation.
Reporter assays
The primer FXNPrF was used as the forward primer for
all constructs. This primer has an MluI site at its 50 end
and primes 1118bp upstream of the start of FXN
translation. Each of the reverse primers contained the
splice acceptor site from the 30 end of intron 1 and an NcoI
site and were designed so that the FXN coding sequence in
exon 1 would be translated in frame with the luciferase
open reading frame from pGL3-Basic (Promega,
Madison, WI, USA). After PCR ampliﬁcation, the gel-
puriﬁed fragment was digested with MluI and NcoI
and cloned into pGL3-Basic. The numbers in the
construct names are based on the location of the reverse
primer in the chromosome 9 sequence from the May 2004
freeze of the human genome in the UCSC database
with the numbering starting at 68 800 000. Thus the 30 end
of the FXN sequence in construct FXN80940 corresponds
to base 68 880 940 in the chromosome 9 sequence.
FXN81423 contains 1006 bases from the 50 end of intron
1 terminating at position 68 881 423, and FXN81658
contains the ﬁrst 1241 bases of intron 1 and terminates at
position 68 881 658. FXN E-box/Mtþ and FXN E-box/
Mt  clones were generated using reverse primers that
contain either the FXN intron E-box/Mt sequence or
the sequence immediately downstream of this region. The
resultant clones diﬀer only by eight bases. The second C
Table 1. Oligonucleotides used in these experiments
Primers
FXNMe74-F 50-TTTTTCTCGAGAATAAGGTATAGAGAGGTTAATTAATTTGTTTTTTGGTTATA-30
FXNMe956-R 50-TTTTTGAATTCCCCTCCACCAACCTACCCTACCTTC-30
FXNMe1212-F 50-TTTTTCTCGAGGAGGTGAAATTTTTAGAGTTGTAGAATAGTTAGAGTAGTAG-30
FXNMe1930-R 50-TTTTTGAATTCACCTCCCAAAATACTAAAATTATAAACATAAACCA-30
FXNPrF 50-TTTTTTACGCGTGCTATGATGGCCGGGCTGGAATGCTGTGGCTATTCACAG-30
FXN-Luc-F1 50-ACCGACATCGATGCGACCT-30
FXN-Luc-R2 50-TTGCTCTCCAGCGGTTCCATCTT-30
FXNchip-QF1 50-GCAAAGGCCAGGAAGGCGGA-30
FXNchip-QR1 50-ATGGCTTGGACGTGGCCTGC-30
Double-stranded oligonucleotides (for EMSAs)
E-boxcon 50-ATCTGTATCACGTGTGTAGTCGTGATG-30
FXN E-box 50-GAACTTCCCACACGTGTTATTTGGCCCACA-30
FXN E-box 50-ACACGTGTTATTTGGCCCAC-30
3384 Nucleic Acids Research, 2007, Vol. 35, No. 10in the E-box core sequence 50-CACGTG-30 can be
methylated by M.eco72I, a DNA methyltransferase from
Escherichia coli RFL72 (17). Methylation was carried out
as previously described (18), and the extent of methylation
checked by digestion with PmlI, a restriction enzyme
whose cleavage is blocked by M.eco72I methylation.
Reporter assays were carried out using mouse C2C12
myoblasts as previously described (19). To assess any
diﬀerences in the RNA stability of these constructs, cells
were treated 24h post-transfection with 5mg/ml actino-
mycin D. RNA and protein samples were collected after
8h. The luciferase protein levels were determined as
previously described (19). The luciferase mRNA levels
were determined by real-time PCR as described below.
The RNA and protein values after 8h of actinomycin
treatment were calculated as the percentage of the values
obtained at 0h.
Electrophoretic mobility shiftassays (EMSAs)
A double-stranded oligonucleotide FXN E-box was
radiolabeled using [g-P
32] ATP (MP Biomedicals, Solon,
OH) and T4 polynucleotide kinase (New England Biolabs,
Beverly, MA, USA) according to standard procedures.
Nuclear extracts were prepared from C2C12 cells using
NE-PER Nuclear Extraction Reagents (Pierce, Rockford,
IL, USA) according to the supplier’s instructions. Binding
was carried out at 208C for 30min in 30ml of reaction
buﬀer containing 5mg of nuclear extract, 25mM HEPES
(pH 7.5), 100mM NaCl, 1mM EDTA and 4mM DTT
with 0.005 pmol of labeled probe. A 1000-fold molar
excess of oligonucleotides containing a consensus E-box,
E-boxcon, the FXN E-box and FXN E-box were used
as competitors in this assay. The samples were subjected
to electrophoresis on 5% native polyacrylamide
(60:1, acrylamide:bisacrylamide) gels.
Real-time RT–PCR
Total RNA was isolated from the cell lines using Trizol
(Invitrogen Life Technologies Inc.) and reverse tran-
scribed using SuperScript
TM III RT First strand synthesis
system for RT–PCR (Invitrogen Life Technologies Inc.),
as per the manufacturer’s instructions. Real-time PCRs
for measuring the endogenous FXN, GUS and 18S RNA
were carried out using an ABI 7500 FAST PCR system
(Applied Biosystems, Foster City, CA, USA) and appro-
priate Taqman probe primer mixes (Applied Biosystems).
Quantitation of luciferase mRNA was carried out using
Power SYBR Green PCR mix (Applied Biosystems) and
the primer pair FXN-Luc-F1 and FXN-Luc-R2 which
ampliﬁes across the intron between the Frataxin exon 1
and the luciferase coding sequence.
Chromatin immunoprecipitation assays
The anti-dimethyl-Histone H3 (Lys9) (H3K9me2) anti-
body (Cat. no. 07-441) was purchased from Upstate
(Charlottesville, VA, USA). The rabbit preimmune serum
was purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). The ChIP assay kit from
Upstate was used according to the manufacturer’s
instructions with slight modiﬁcations. Brieﬂy, cells were
cross-linked in RPMI medium 1640 with 1% formalde-
hyde at 238C for 5min. The cells were washed in PBS and
lysed in a buﬀer containing 1% SDS, 10mM EDTA and
50mM Tris–HCl pH 8.0. The chromatin from lysed cells
was sonicated to lengths between 200 and 1000bp using a
Bioruptor sonicator (Diagenode, Philadelphia, PA, USA)
and the cell debris was removed by centrifugation.
The sonicated lysates were precleared and incubated
with either preimmune serum or the anti-H3K9Me2
antibody at 48C overnight. The immunocomplexes were
recovered by Protein A agarose, washed and eluted in 1%
SDS, 0.1M NaHCO3 and the crosslinking reversed by
incubation at 658C for 4h in 200mM NaCl. The samples
were phenol: chloroform extracted and ethanol precipi-
tated in the presence of Pelletpaint (EMD Biosciences, San
Diego, CA, USA). The amount of FXN DNA immuno-
precipitated was determined using quantitative real-time
PCR using Power SYBR green PCR master mix
(Applied Biosystems). The PCR primers used were
FXNchip-QF1 and FXNchip-QR1. The ChIP experiments
were performed in triplicate and each PCR reaction was
done in duplicate. The immunoprecipitated DNA was
normalized to the amount of input DNA and plotted as
the fold enrichment over the preimmune serum (IgG).
RESULTS AND DISCUSSION
We have previously analyzed the region upstream of the
transcription start site of the FXN gene and identiﬁed the
regulatory elements important for FXN promoter activity
(19). However, almost nothing was known about the
region of intron 1 containing the FXN repeat. Since
sequences important for promoter activity can be located
in the ﬁrst intron (10–13) and the sequences closest to the
repeat are the ones most likely to be aﬀected by repeat
expansion, we set out to examine this region in some
detail. The organization of the 50 end of the FXN gene is
shown in Figure 1A. Intron 1 is 10 436bp long. The FXN
repeat is located 1340bp from the beginning of the intron.
The region of intron 1 between exon 1 and the FXN repeat
contains three interspersed repeated DNA elements. This
includes a member of the ancient MIRb family of repeated
DNA elements that is thought to have been active in
transposition before the mammalian radiation, Charlie8, a
member of the primate-speciﬁc MER1 (medium reitera-
tion 1) family (20) and the ﬁrst half of the Alu element
from which the FXN repeat is thought to have been
derived (21).
Intron1in affected and unaffected individuals
showdifferences in DNA methylation
Since repeat-mediated epigenetic changes have been
suggested to occur in regions containing expanded FXN
repeats (8), we examined the methylation changes in the
sequence immediately upstream of the FXN repeat.
Bisulﬁte analysis demonstrates that a number of CpG
residues were methylated in cell lines from both individ-
uals with FRDA and unaﬀected individuals (Figure 2).
However, the average methylation density was  50%
higher in cells from aﬀected individuals (compare the
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3386 Nucleic Acids Research, 2007, Vol. 35, No. 10heights of the black and gray bars in Figure 2). This
reﬂects, in part, the fact that the methylation density
decreased more slowly 50 of the repeat tract in these cells.
The basal level of methylation seen in unaﬀected
individuals may be due to methylation spreading from
the downstream Alu element since these elements are
themselves frequently methylated (22). In addition to an
overall increase in methylation in FRDA cells, certain
residues were much more likely to be methylated in these
cells than in those without the disease. For example
residues 3, 6, and 13 are methylated in 75–100% of alleles
from patients, while they were completely free from
methylation in unaﬀected individuals (Figure 2). DNA
from fresh blood of four unrelated individuals with
FRDA showed a similar methylation of residues 3, 6
and 13 to DNA (data not shown), suggesting that this
methylation is not an artifact of the transformation
process. Thus normal alleles seem to have a naturally
occurring ‘methylation footprint’ that is absent from
FRDA alleles. The elevated level of methylation seen in
FRDA cells disappeared 50 of residue 3 with overall levels
of methylation in both populations falling to 20% at
residue 1. Thus the repeat-mediated increase in DNA
methylation is limited to the region immediately adjacent
to the repeat. This conclusion is consistent with the lack
of any DNA methylation in the promoter of either
population group (data not shown).
Intron 1contributes to FXN promoter activity
The methylation ‘footprints’ at residues 3, 6 and 13 in
unaﬀected individuals could reﬂect either the existence of
positioned nucleosomes or binding of sequence-speciﬁc
DNA-binding proteins. If the latter were true, we
might expect that deletion of these regions could aﬀect
FXN promoter activity in transient transfection assays.
We therefore generated reporter constructs containing
the promoter, exon 1, and various lengths of intron 1.
Downstream of the intron 1 sequence in each construct
was the branch and splice acceptor sites from the end of
intron 1, and the luciferase coding sequence. The results of
transfections of these constructs into mouse C2C12
myoblasts are shown in Figure 3A. The longest construct
tested, FXN81658 contained the region of intron 1 from
the end of exon 1 to just 50 of the FXN repeat that
encompasses all three protected residues. This construct
gave the highest luciferase activities of all the constructs
tested with an activity that was  45-fold above that of
the empty vector. A construct FXN81423 that terminated
235 bases 50 of the sequence in FXN81658, and therefore
that lacked residue 13, had a luciferase activity that was
only  10% that of the full length construct FXN81658
(Figure 3A). A construct FXN80940 that terminated 718
bases 50 of FXN81423, and thus lacked residue 3 and 6 had
an activity very similar to that of FXN81423. As can be
seen from Figure 3D, treatment of FXN81658 and
FXN81423 transfected cells with the transcription inhibi-
tor Actinomycin D resulted in very similar levels of
luciferase protein and mRNA after 8h of treatment.
This suggests that the absolute diﬀerence in luciferase
activity between the two constructs reﬂects diﬀerences in
transcription rates rather than diﬀerences in RNA
stability. Thus, it is likely that the 235bp region of
intron 1 containing residue 13 has a binding site for one or
more transcription factors that make a signiﬁcant positive
contribution to the FXN promoter activity.
Residue 13 is located within a putative E-box. This site
overlaps with a binding site for the muscle speciﬁc Mt
transcription factor. We generated two constructs
Figure 2. Methylation status of 15 CpG residues in the region 50 of the FXN repeat in cells from unaﬀected and aﬀected individuals. DNA from
lymphoblastoid cell lines from four unaﬀected individuals and four individuals with FRDA was bisulphite modiﬁed and cloned as described in the
Materials and Methods section. The numbers below the bars indicate the residue number using the same numbering convention used in Figure 1.
The gray arrows indicate the three residues that are frequently methylated in aﬀected individuals but that are very infrequently methylated, if at all,
in the unaﬀected population.
Nucleic Acids Research, 2007, Vol. 35,No. 10 3387diﬀering only in eight bases. The ﬁrst construct included
the E-box/Mt-binding site and the second terminated
just 50 of the E-box and was thus missing both sites.
We measured the activity of these constructs in C2C12
cells. The construct lacking the E-box/Mt-binding site
had a signiﬁcantly lower luciferase activity than the
construct containing these regions (Figure 3B). As can
be seen from Figure 3D, Actinomycin D treatment had
a similar eﬀect on the yield of luciferase RNA and
protein of both of these constructs. These ﬁndings
support the idea that the original diﬀerences in
luciferase activity we observe without Actinomycin D
reﬂects a higher promoter activity for the construct
with the E-box/Mt-binding site rather than enhanced
mRNA stability.
The E-box/Mtregion binds transcription factors
inextracts frommuscle cells
Three protein–DNA complexes were found in electro-
phoretic mobility shift assays with C2C12 cells using
the E-box/Mt region as a probe (complexes I, II and III in
Figure 4, lane 2). Complexes I and II could be competed
out by addition of E-boxcon, an oligonucleotide that
contains a consensus E-box-binding site. Thus members of
a large family of basic Helix-Loop-Helix E-box-binding
proteins that includes MyoD and c-myc have the potential
to bind this region. Complex III could be competed out by
an oligonucleotide that contains a truncated E-box and
the intact Mt-binding site (FXN E-box, F Figure 4,
lane 5). Complex III thus probably represents the complex
formed by a protein bound at the Mt-binding site.
Thus, a number of proteins have the potential to bind to
this region in vivo.
Specific methylation ofresidue 13 does notaffectFXN
promoter activity
The methylation of the E-box in FRDA patients could
lead to a FXN deﬁcit via a direct eﬀect on the binding
Figure 3. The eﬀect of diﬀerent lengths of intron 1 sequence on the activity of the FXN promoter. (A–C). Luciferase activities of constructs
containing diﬀerent amounts of intron 1. Constructs containing the promoter, exon 1 and diﬀerent lengths of intron 1 sequence were transfected into
mouse myoblasts as described in the Materials and Methods section. The dotted lines demarcate deleted regions. The suﬃx ‘Me’ in the construct
FXN81658Me indicates that the FXN81658 construct was speciﬁcally methylated at the E-box/Mt-binding site. The luciferase levels from the
FXN reporter constructs were normalized to luciferase levels from the pRLNull vector and expressed as a percentage of the normalized luciferase
activity of the full-length construct. The data are an average of three independent transfection experiments. (D) Actinomycin D treatment of cells
transfected with the FXN81658, FXN81423, FXNE-box/Mtþ and FXNE-box/Mt- constructs. The values for the luciferase protein and mRNA
after exposure to Actinomycin D for 8h are shown expressed as a percentage of the values at 0h. The data shown represent the average of three
independent experiments.
Figure 4. Electrophoretic gel mobility shift analysis (EMSA) of proteins
binding to FXN intron 1. EMSA was carried in the presence of molar
excesses of E-boxcon, a canonical E-box sequence, FXN E-box which
contains the FXN E-box together with the muscle-speciﬁc Mt-binding
site, and FXN E-Box which contains the 30 end of the E-box together
with the full Mt-binding site.
3388 Nucleic Acids Research, 2007, Vol. 35, No. 10of one or more DNA-binding proteins. M.eco72I
from E. coli RFL72 is a DNA methyltransferase that
speciﬁcally methylates the CpG residue in the sequence
50-CACGTG-30 (17). Thus the FXN E-box is a substrate
for this enzyme and the site it methylates corresponds to
residue 13. Since there are no other sites that can be
methylated by this enzyme in the reporter construct, this
methylase can be used to examine the eﬀect of methylation
of this residue speciﬁcally. Methylation had no eﬀect on
the activity of a reporter construct transfected into C2C12
cells (Figure 3C). Thus methylation of residue 13 per se is
unlikely to be the primary cause of the FXN deﬁciency.
Affected individuals have elevatedlevels of H3K9Me2
Increased methylation of residue 13 may be a secondary
consequence of a more compact chromatin organization
which blocks factor binding. Since chromatin compaction
is associated with elevated levels of H3K9Me2, we
analyzed intron 1 in four FRDA patients for the presence
of this histone modiﬁcation. Elevated levels of H3K9Me2
were seen in these individuals (Figure 5A), all of whom
had FXN mRNA levels 10–30% that of unaﬀected
individuals (Figure 5B). While this manuscript was
in preparation a similar observation was reported
for another lymphoblastoid cell line from a FRDA
patient (23). The increase in H3K9Me2 is consistent
with the fact that treatment of FRDA lymphocytes with
histone deacetylase inhibitors increases FXN transcrip-
tion signiﬁcantly (23) since H3K9 acetylation blocks K9
methylation. Our data thus support the idea that
a chromatin-based mechanism is responsible for the
FXN mRNA deﬁcit in FRDA (23).
The altered chromatin conformation may decrease
transcription by impeding transcription elongation (9).
Our data also suggests another way in which the
chromatin modiﬁcation at the FXN gene can lead to the
mRNA deﬁcit. In the absence of an expanded repeat
tract, intron 1 binds proteins that positively aﬀect
FXN transcription. A secondary eﬀect of this binding is
that it creates natural ‘methylation footprints’ by protect-
ing the binding sites from DNA methylation (Figure 6).
The more compact chromatin formed on alleles with large
FXN repeats blocks access of these proteins to the DNA
as evidenced by disappearance of the ‘methylation
footprints’. Absence of binding of these transcription
factors may lead to a reduction in transcription initiation.
One implication of this model is that DNA methylation
may be a secondary consequence of the histone modiﬁca-
tions. This may explain why histone deacetylase inhibitors
are so eﬀective at increasing FXN gene expression in
FRDA cells (23).
How could the long FXN-repeat tracts in patient cells
generate transcriptionally silent chromatin? One possibi-
lity is that this process involves small double-stranded
RNAs (dsRNAs) that target the transcriptional silencing
machinery to homologous regions of the genome (24).
Potential sources of these dsRNAs are regions of
transcripts that can form hairpins (25) or overlapping
sense and antisense transcripts (26). Long GAA-repeat
tracts form DNA hairpins (27). This raises the possibility
Figure 5. FXN histone H3 K9 dimethylation and mRNA levels in
unaﬀected and aﬀected individuals. (A) The amount of FXN DNA
immunoprecipitated by antibodies to histone H3-K9Me2 in each
lymphoblastoid cell line was determined by real-time PCR as described
in the Materials and Methods section. The data shown is an average of
three independent ChIP experiments. In all instances P50.002. When
the data from all the patient samples was combined and compared to
the combined data from the unaﬀected individuals P¼0.0001. (B) FXN
RNA levels were determined in the indicated cell lines using real-time
PCR and expressed relative to the amount of GUS mRNA in the
same cells.
Figure 6. Model for chromatin organization in the region containing
residue 13 in normal and FRDA alleles.
Nucleic Acids Research, 2007, Vol. 35,No. 10 3389that RNA containing these repeats may also do so.
However, since a low level of modiﬁed chromatin exists at
the frataxin locus even when the repeat number is too
small to form stable hairpins, it is tempting to speculate
that an antisense mechanism is involved at least when the
repeat number is low.
Repeat-mediated heterochromatin formation is seen in
two other Repeat Expansion diseases: Fragile X syndrome
and the congenital form of Myotonic Dystrophy type 1
(7). Thus repeat-mediated transcriptional silencing may
provide a common thread linking these diseases where the
repeat is transcribed but not translated.
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